Vir Biotechnology, Inc.
Biotechnology Research
San Francisco, California 31,856 followers
Powering the Immune System to Transform Lives
Leadership
-
Marianne D. De Backer, MSc, PhD, MBA
CEO Vir Biotechnology, Inc. Board Member. Passionate about making a difference for patients.
-
Jennifer Towne
Executive Vice President and Chief Scientific Officer at Vir Biotechnology
-
Jeff Calcagno, MD
Physician executive focused on growing innovative life sciences companies
Applying Immunological Insights to Infectious Disease and Beyond
Our world class, proprietary monoclonal antibody (mAb) discovery platform is a core strength upon which we continue to build and improve. Leveraging this platform, we are able to identify rare and broad antibodies with enhanced selectivity and potency using artificial intelligence-led (AI) protein engineering.
Discover Our TechnologiesT Cell-Based Viral Vector Platform: a Unique Approach to Powering the Immune System
Our unique T cell-based viral vector platform, which is currently being used to develop a vaccine for HIV, has the potential to be more broadly applicable to infectious disease, oncology and beyond. Human cytomegalovirus is the most potent inducer of an immune response of any known human virus. HCMV-based vaccines have the potential to generate T cells that identify HIV infected cells in ways that the virus does not know how to subvert.